CR20170579A - Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. - Google Patents

Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres.

Info

Publication number
CR20170579A
CR20170579A CR20170579A CR20170579A CR20170579A CR 20170579 A CR20170579 A CR 20170579A CR 20170579 A CR20170579 A CR 20170579A CR 20170579 A CR20170579 A CR 20170579A CR 20170579 A CR20170579 A CR 20170579A
Authority
CR
Costa Rica
Prior art keywords
peptides
cancer
combination
relates
present
Prior art date
Application number
CR20170579A
Other languages
English (en)
Inventor
Toni Weinschenk
Andrea Mahr
Oliver; Schoor
Harpreet; Singh
Jens; Fritsche
Colette; Song
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1511792.2A external-priority patent/GB201511792D0/en
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of CR20170579A publication Critical patent/CR20170579A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)

Abstract

La presente invención se relaciona con péptidos, proteínas, ácidos nucleicos y células para usar en métodos inmunoterapéuticos. En particular, la presente invención se relaciona con la inmunoterapia de cáncer. La presente invención además se relaciona con epitopes peptídicos de células T asociados a tumor, solos o en combinación con otros péptidos asociados a tumor que por ejemplo pueden servir como ingredientes farmacéuticos activos de composiciones de vacuna que estimulan respuestas inmunológicas antitumorales, a para estimular a células T ex vivo y transferirlas a los pacientes. Los péptidos unidos a las moléculas del complejo mayor de histocompatibilidad (MHC), o los péptidos como tal, también pueden ser blancos de anticuerpos, receptores solubles de células T, y de otras moléculas de unión.
CR20170579A 2015-07-06 2016-07-05 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. CR20170579A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562188870P 2015-07-06 2015-07-06
GBGB1511792.2A GB201511792D0 (en) 2015-07-06 2015-07-06 Novel peptides and combination of peptides for use in immunotherapy against esopageal cancer and other cancers
PCT/EP2016/065812 WO2017005733A2 (en) 2015-07-06 2016-07-05 Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers

Publications (1)

Publication Number Publication Date
CR20170579A true CR20170579A (es) 2018-05-25

Family

ID=56368954

Family Applications (3)

Application Number Title Priority Date Filing Date
CR20230563A CR20230563A (es) 2015-07-06 2016-07-05 NUEVOS PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS PARA USAR EN INMUNOTERAPIA CONTRA EL CÁNCER ESOFÁGICO Y OTROS CÁNCERES (Divisional Exp. 2017-0579)
CR20170579A CR20170579A (es) 2015-07-06 2016-07-05 Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres.
CR20230562A CR20230562A (es) 2015-07-06 2016-07-05 NUEVOS PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS PARA USAR EN INMUNOTERAPIA CONTRA EL CÁNCER ESOFÁGICO Y OTROS CÁNCERES (Divisional Exp. 2017-000579)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR20230563A CR20230563A (es) 2015-07-06 2016-07-05 NUEVOS PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS PARA USAR EN INMUNOTERAPIA CONTRA EL CÁNCER ESOFÁGICO Y OTROS CÁNCERES (Divisional Exp. 2017-0579)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20230562A CR20230562A (es) 2015-07-06 2016-07-05 NUEVOS PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS PARA USAR EN INMUNOTERAPIA CONTRA EL CÁNCER ESOFÁGICO Y OTROS CÁNCERES (Divisional Exp. 2017-000579)

Country Status (33)

Country Link
US (21) US10487132B2 (es)
EP (2) EP4321172A2 (es)
JP (3) JP6944382B2 (es)
KR (1) KR20180026758A (es)
CN (2) CN113880938A (es)
AU (3) AU2016289754B2 (es)
BR (1) BR112017028363A2 (es)
CA (2) CA2991396A1 (es)
CL (7) CL2017003361A1 (es)
CO (1) CO2017012886A2 (es)
CR (3) CR20230563A (es)
DK (1) DK3319985T3 (es)
EA (1) EA201792671A1 (es)
ES (1) ES2841507T3 (es)
HK (1) HK1255542A1 (es)
HR (1) HRP20210076T1 (es)
HU (1) HUE052628T2 (es)
IL (1) IL256303A (es)
LT (1) LT3319985T (es)
MA (1) MA51531A (es)
MD (1) MD3319985T2 (es)
MX (2) MX2017017148A (es)
MY (1) MY188354A (es)
PE (3) PE20180259A1 (es)
PH (1) PH12018500004A1 (es)
PL (1) PL3319985T3 (es)
PT (1) PT3319985T (es)
RS (1) RS61203B1 (es)
SG (1) SG10202001668PA (es)
SI (1) SI3319985T1 (es)
TW (2) TW202222825A (es)
UA (1) UA124411C2 (es)
ZA (1) ZA201707810B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109628591B (zh) * 2018-12-04 2022-04-15 南方医科大学南方医院 用于肺腺癌预后预测的标志物
CN112007167B (zh) * 2020-08-29 2023-01-24 南京中医药大学 蟾酥多肽在作为蟾蜍甾烯促渗剂中的应用
CN112812197B (zh) * 2021-01-11 2022-05-31 中国药科大学 一种兰州百合多糖及其制备方法和应用
CN114057860B (zh) * 2021-11-09 2023-10-20 中国科学技术大学 特定组氨酸甲基化修饰的s100a9蛋白免疫原、多克隆抗体及其制备方法
CN114717191B (zh) * 2022-04-26 2023-06-16 兰州大学第一医院 一株人肝内胆管癌细胞株icc-x3及其应用
CN115322967B (zh) * 2022-06-13 2023-08-08 浙江省人民医院 一种永生化人甲状腺乳头状癌成纤维细胞株及其构建方法和应用
CN114957399B (zh) * 2022-06-29 2023-05-09 湖北工业大学 一种多肽、多肽衍生物及其在制备抗肿瘤药物中的应用
CN116183920B (zh) * 2022-09-22 2023-10-20 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于检测鼻咽癌预后的抗体组合、系统及应用
CN116144772B (zh) * 2022-11-18 2023-08-25 昆明医科大学第一附属医院 一种Hsa_circ_0006117在制备治疗肺腺癌药物中的应用
CN115737619A (zh) * 2022-11-21 2023-03-07 深圳承启生物科技有限公司 一种用于抑制肿瘤的药物靶点、用途及口服药物
CN116676334A (zh) * 2023-02-08 2023-09-01 深圳大学 抑郁症动物模型的构建方法
CN117843721B (zh) * 2024-03-07 2024-05-10 鲁东大学 一种扇贝源抗氧化肽及其制备方法与应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
DK171727B1 (da) 1978-12-22 1997-04-14 Biogen Inc Rekombinante hepatitis B virus DNA-molekyler, værtsorganismer transformeret hermed, HBV-antigenspecifikke polypeptider, DNA-sekvenser kodende for HBV-antigenspecifikke polypeptider, metoder til påvisning af hepatitis B virus-antistoffer, metoder til fremstilling af nævnte DNA-molekyler, fremgangsmåder til fremstilling af nævnte polypeptider og midler til påvisning af HBV-infektion
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
CA2163032C (en) 1993-06-03 2001-02-06 John Landon Antibody fragments in therapy
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
ATE244300T1 (de) 1996-01-17 2003-07-15 Imp College Innovations Ltd Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2287254A1 (en) * 1997-04-21 1998-10-29 Schering Corporation Mammalian cytokines; related reagents and methods
WO1999006550A2 (en) 1997-08-01 1999-02-11 Genset 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE
JP5456222B2 (ja) 1998-12-23 2014-03-26 ジェネンテック， インコーポレイテッド Ｉｌ−１関連ポリペプチド
WO2001072768A2 (en) 2000-03-27 2001-10-04 Technion Research And Development Foundation Ltd. Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
EP1289564B1 (en) 2000-06-05 2018-07-18 Altor BioScience Corporation T cell receptor fusions and conjugates and methods of use thereof
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
US7569664B2 (en) 2002-10-09 2009-08-04 Immunocore Limited Single chain recombinant T cell receptors
US7378495B2 (en) * 2002-10-21 2008-05-27 Pevion Biotech, Ltd. PTH-rP related peptide cancer therapeutics
CA2505558C (en) 2002-11-09 2013-07-02 Avidex Limited T cell receptor display
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
US20040220094A1 (en) 2003-05-01 2004-11-04 Skinner Keith K. Inverse agonist and agonist peptides that stimulate/inhibit hair growth
JP5150909B2 (ja) * 2005-07-27 2013-02-27 オンコセラピー・サイエンス株式会社 食道癌を診断する方法
ATE461214T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
DE602005016112D1 (de) * 2005-09-05 2009-10-01 Immatics Biotechnologies Gmbh Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe
WO2008013934A2 (en) * 2006-07-27 2008-01-31 Cell Signaling Technology, Inc. Tyrosine phosphorylation sites
MX341064B (es) * 2006-09-08 2016-08-05 Amgen Inc * Variantes de la familia il-1.
MX2010001086A (es) * 2007-07-27 2010-04-09 Immatics Biotechnologies Gmbh Nueva inmunoterapia contra tumores neuronales y cerebrales.
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
WO2010120554A1 (en) * 2009-04-01 2010-10-21 The Regents Of The University Of California Detecting and treating breast cancer resistance to egfr inhibitors
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201009222D0 (en) 2010-06-02 2010-07-21 Immatics Biotechnologies Gmbh Improved cancer therapy based on tumour associated antigens derived from cyclin D1
BR112013010213A2 (pt) 2010-10-26 2019-09-24 Technion Research & Development Foundation Ltd anticorpos que unem ligantes solúveis de receptores de célula t
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
US20190292535A1 (en) 2012-11-08 2019-09-26 Roche Diagnostics Operations, Inc. Nucleic acids encoding chimeric polypeptides for library screening
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
TWI777197B (zh) * 2013-08-05 2022-09-11 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（六）

Also Published As

Publication number Publication date
SG10202001668PA (en) 2020-04-29
MY188354A (en) 2021-12-02
CL2023000708A1 (es) 2023-08-18
US11939366B2 (en) 2024-03-26
CL2021000981A1 (es) 2021-09-10
US10626162B2 (en) 2020-04-21
US11401319B2 (en) 2022-08-02
AU2022205209B2 (en) 2024-05-09
HUE052628T2 (hu) 2021-05-28
HRP20210076T1 (hr) 2021-05-14
AU2016289754A1 (en) 2017-11-30
US20220119487A1 (en) 2022-04-21
AU2016289754B2 (en) 2021-02-18
US20220106379A1 (en) 2022-04-07
MX2017017148A (es) 2018-02-23
PH12018500004A1 (en) 2018-07-09
EP4321172A2 (en) 2024-02-14
US11359003B2 (en) 2022-06-14
DK3319985T3 (da) 2021-01-04
US11608370B2 (en) 2023-03-21
PE20240778A1 (es) 2024-04-17
CA3221001A1 (en) 2017-01-12
US10703795B2 (en) 2020-07-07
US20220119484A1 (en) 2022-04-21
CN107912043A (zh) 2018-04-13
US11999774B2 (en) 2024-06-04
US20210024609A1 (en) 2021-01-28
US20200157176A1 (en) 2020-05-21
US20210277088A1 (en) 2021-09-09
US11932678B2 (en) 2024-03-19
CL2021000979A1 (es) 2021-09-10
MX2021013003A (es) 2022-01-18
ZA201707810B (en) 2018-11-28
CL2021000982A1 (es) 2021-09-10
MA51531A (fr) 2020-11-11
CR20230563A (es) 2024-01-22
US10829537B2 (en) 2020-11-10
US20210277087A1 (en) 2021-09-09
US20220106380A1 (en) 2022-04-07
UA124411C2 (uk) 2021-09-15
MD3319985T2 (ro) 2021-01-31
JP2018519825A (ja) 2018-07-26
US20220135646A1 (en) 2022-05-05
US20220098276A1 (en) 2022-03-31
CL2021000980A1 (es) 2021-09-10
US20220119486A1 (en) 2022-04-21
CL2017003361A1 (es) 2018-05-04
TW202222825A (zh) 2022-06-16
PL3319985T3 (pl) 2021-05-04
CR20230562A (es) 2024-01-22
SI3319985T1 (sl) 2021-01-29
AU2022205209A1 (en) 2022-08-04
US20220135647A1 (en) 2022-05-05
JP6944382B2 (ja) 2021-10-06
KR20180026758A (ko) 2018-03-13
PE20231014A1 (es) 2023-07-05
US20220112266A1 (en) 2022-04-14
EP3736283A1 (en) 2020-11-11
CA2991396A1 (en) 2017-01-12
US20190315832A1 (en) 2019-10-17
US20200010531A1 (en) 2020-01-09
EA201792671A1 (ru) 2018-06-29
CN113880938A (zh) 2022-01-04
CO2017012886A2 (es) 2018-03-09
CN107912043B (zh) 2022-02-18
AU2021200800B2 (en) 2022-08-18
TWI776332B (zh) 2022-09-01
JP2024041841A (ja) 2024-03-27
RS61203B1 (sr) 2021-01-29
PT3319985T (pt) 2021-01-06
US20220119485A1 (en) 2022-04-21
BR112017028363A2 (pt) 2018-08-28
US20220135648A1 (en) 2022-05-05
AU2021200800A1 (en) 2021-03-04
IL256303A (en) 2018-02-28
US10487132B2 (en) 2019-11-26
US20200291088A1 (en) 2020-09-17
HK1255542A1 (zh) 2019-08-23
US20220098277A1 (en) 2022-03-31
JP2022020614A (ja) 2022-02-01
ES2841507T3 (es) 2021-07-08
US20210277086A1 (en) 2021-09-09
US20220098275A1 (en) 2022-03-31
PE20180259A1 (es) 2018-02-05
TW202124430A (zh) 2021-07-01
CL2023000706A1 (es) 2023-08-18
LT3319985T (lt) 2020-12-28

Similar Documents

Publication Publication Date Title
AR121380A2 (es) Péptidos y combinación de péptidos y andamiajes para su uso en inmunoterapia contra carcinoma de células renales (rcc) y otros cánceres
AR127117A2 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
CO2018002202A2 (es) Péptidos y combinaciones de péptidos para inmunoterapia contra el cáncer de próstata y otros tipos de cáncer
CO2017008902A2 (es) Péptidos y nuevas combinaciones de péptidos para inmunoterapia contra el cáncer de pulmón, incluido el cáncer de pulmón amicrocítico y otros tipos de cáncer
CL2021000982A1 (es) Nuevos péptidos y combinación de péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres. (divisional de la solicitud no. 201703361)
CO2018000252A2 (es) Péptidos y combinaciones de péptidos para inmunoterapia contra el cáncer epitelial de ovario y otros tipos de cáncer
CO2018010284A2 (es) Tratamientos contra el cáncer de útero
PE20181164A1 (es) Nuevos peptidos, combinaciones de peptidos y soportes para el uso en el tratamiento inmunoterapeutico de varios tipos de cancer
CO2017012891A2 (es) Péptidos y combinaciones de péptidos para la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
CR20180191A (es) Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer microcítico de pulmón y otros tipos de cáncer
CR20180051A (es) Nuevos epítopos celulares y nuevas combinaciones de epítopos celulares para el uso en la inmunoterapia del mieloma y de otros tipos de cáncer.
CO2018000245A2 (es) Péptidos y combinaciones de péptidos para inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer
CR20220115A (es) PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Div. 2017-522)
CO2018002902A2 (es) Péptidos y combinaciones de péptidos para el tratamiento inmunoterapéutico de varios tipos de cáncer
CO2018004869A2 (es) Péptidos y combinación de péptidos para inmunoterapia contra varios tipos de cáncer
CO2018012294A2 (es) Inmunoterapia contra el melanoma y otros tipos de cáncer
CL2023001324A1 (es) Péptidos, combinaciones, células para inmunoterapia contra cáncer de vejiga y otros cánceres
CO2017009101A2 (es) Péptidos y combinación de péptidos
CO2017010830A2 (es) Péptidos y combinaciones de péptidos y de soportes
CO2018006022A2 (es) Epítopos celulares y combinaciones de epítopos celulares para inmunoterapia del mieloma y de otros tipos de cáncer
AR124242A2 (es) Péptidos para usar en inmunoterapia contra el cáncer esofágico y otros cánceres
AR122218A2 (es) Péptidos y soportes útiles en el tratamiento inmunoterapéutico de varios tipos de cáncer
CR20170522A (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores